After a terrible 2016, perhaps the worst in a decade, the biotech sector has had a fairly decent run this year. The iShares NASDAQ Biotechnology Index (ETF) has returned over 21% so far this year while it was down 11% last year. An increase in the number of new drug approvals, drug innovation, improving earnings growth, and encouraging broader market have helped bolster the sector.
from RTT - Biotech http://ift.tt/2BYA43C
via IFTTT
No comments:
Post a Comment